NYSE:BIOLife Sciences
The Bull Case For Bio-Rad Laboratories (BIO) Could Change Following Citigroup’s Downgrade To Neutral
In early April 2026, Citigroup downgraded Bio-Rad Laboratories’ rating from “Buy” to “Neutral,” signaling a shift in analyst sentiment toward the life science and clinical diagnostics company.
This reassessment comes as Bio-Rad is cited among key players in the rapidly expanding single-cell omics market, where demand for advanced tools in cancer, immunology, and stem cell research is intensifying.
We’ll now examine how Citigroup’s downgrade, against a backdrop of growing single-cell omics...